Clinical trial · Observational
Cognitive Impairment in Older Adults With Hematologic Malignancies
Prevalence of Cognitive Impairment and Its Association With Activities of Daily Living Among Older Adults With Hematologic Malignancies Receiving Chemotherapy
NCT07842679CI-TRIAL-00126629not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260929-000001
Summary
Brief summary (as posted)
This cross-sectional study aims to determine the prevalence of cognitive impairment and evaluate its relationship with activities of daily living among older adults with hematologic malignancies receiving chemotherapy.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chemotherapy Effect | — | UNRESOLVED | — |
| Cognitive Impairment | — | UNRESOLVED | — |
| Hematologic Malignancies | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Single cohort: Older adults with hematologic malignancies
- description
- Adults aged 65 years or older with hematologic malignancies receiving chemotherapy who will undergo cognitive and functional assessment.
Primary outcomes (1)
- measure
- Prevalence of cognitive impairment
- timeFrame
- Baseline
- description
- Proportion of participants with cognitive impairment defined as a Montreal Cognitive Assessment (MoCA) score less than 26.
Secondary outcomes (5)
- measure
- Mean MoCA score
- timeFrame
- Baseline
- description
- Mean Montreal Cognitive Assessment (MoCA) score (range 0-30, higher scores indicate better cognition)..
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * \- Age 65 years or older * Confirmed diagnosis of hematologic malignancy * Currently receiving chemotherapy * Able to communicate and participate in cognitive assessment * Written informed consent Exclusion Criteria: * \- Previously diagnosed dementia before the diagnosis of malignancy * Delirium at the time of assessment * Severe visual or hearing impairment interfering with cognitive testing * History of major neurological disorders affecting cognition * Severe psychiatric illness affecting cognitive assessment * Critically ill patients unable to complete study assessment
References
Publications (0)
Data not yet available
No reference posted for this study.